Dr Reddy reports three FDA observations before October 23 results for Dr Reddy stock

Published on 10/16/2026 at 11:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A Form 483 followed an October 8-9 inspection at FTO-9 in India. Dr Reddy stock has results due on October 23, 2026.

Regulatory update and earnings calendar

Dr Reddy disclosed three FDA observations after an October 14, 2026 filing.
First-quarter FY27 revenue fell 5.4 percent to INR 80.9 billion.
Dr Reddy stock was trading at INR 1,226.70 at 2:34 p.m. IST on October 16, 2026.

Dr Reddy stock, pharmaceuticals, FDA inspection, BSE, BSE Sensex, Illustration mit AI erstellt.

Dr Reddy reported three FDA observations at its FTO-9 manufacturing facility after an inspection from October 8 to October 9, 2026. The filing dated October 14, 2026, said the company would address the observations within the stipulated timeline, according to StockTitan.

FDA observations set the immediate tone

The inspection covered the FTO-9 facility in Visakhapatnam, Andhra Pradesh, which produces injectable medicines. A Form 483 records inspection observations and requires a company response, making the regulatory follow-up the near-term issue for the manufacturing site.

The disclosure did not include a financial estimate linked to the observations. That leaves the October 23 results as the next scheduled test for operating performance and management commentary.

What do the latest numbers show?

Dr Reddy reported first-quarter fiscal 2027 revenue of INR 80.9 billion, down 5.4 percent year over year after adjusting for the semaglutide-related impact. Adjusted profit after tax was INR 6.5 billion, down 54 percent year over year, while adjusted EBITDA was INR 10.9 billion, down 49 percent, according to DSIJ.

The same review put the adjusted EBITDA margin at 13.5 percent, compared with a 15.5 percent estimate from Motilal Oswal Financial Services. North America revenue fell 35 percent year over year to INR 22.0 billion, while India revenue rose 17 percent to INR 17.2 billion. The figures show why the next earnings release matters beyond the inspection headline.

Three dated developments for investors

On July 23, 2026, first-quarter revenue reached INR 80.9 billion, down 5.4 percent year over year, according to DSIJ. On September 29, 2026, Citi raised its target from INR 1,040.00 to INR 1,450.00 and upgraded the stock to Buy, according to MarketBeat. On October 14, 2026, Dr Reddy disclosed three FDA observations at FTO-9, according to StockTitan.

October 23 brings two company dates

The next scheduled dates are October 23, 2026, for the second-quarter fiscal 2027 results and October 23, 2026, at 10:00 a.m. ET for the earnings call, according to MarketBeat.

Stock price and regulatory risk

Dr Reddy stock was trading at INR 1,226.70 on BSE on October 16, 2026, at 2:34 p.m. IST. Its 52-week range was INR 1,025.90 to INR 1,414.40, and its market capitalization was INR 1.0 trillion as of October 16, 2026.